Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer

被引：0
|
作者：
Paul F. Schellhammer
Robert M. Hershberg
机构：
[1] Norfolk,Eastern Virginia Medical School and Devine Tidewater Urology
[2] Seattle,Dendreon Corporation
[3] 6333 Center Drive,Interstate Corporate Center
来源：
World Journal of Urology | 2005年 / 23卷
关键词：
Prostate cancer; Immunotherapy; Vaccine; Androgen independent; Provenge; Hormone refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express unique proteins which serve as highly specific targets. APC8015 (Provenge) is one such investigational therapeutic vaccine that uses autologous antigen presenting cells (APCs) loaded with a recombinant fusion protein of prostatic acid phosphatase linked to a molecule that specifically targets a receptor expressed on the surface of human APCs. Clinical trial outcomes have demonstrated activity in patients with androgen independent prostate cancer.
引用
收藏
页码：47 / 49
页数：2
相关论文
共 50 条
  • [21] Change in prostate specific antigen following androgen stimulation is an independent predictor of prostate cancer diagnosis
    Svatek, Robert S.
    Shulman, Michael J.
    Benaim, Elie A.
    Rogers, Thomas E.
    Margulis, Vitaly
    JOURNAL OF UROLOGY, 2008, 179 (06): : 2192 - 2195
  • [22] Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer
    Benaim, EA
    Page, CM
    Lam, PM
    Roehrborn, CG
    JOURNAL OF UROLOGY, 2002, 168 (01): : 379 - 379
  • [23] GENE-THERAPY FOR THE TREATMENT OF ANDROGEN-INDEPENDENT AND PROSTATE-SPECIFIC ANTIGEN PRODUCING HUMAN PROSTATE-CANCER
    KO, ASC
    THALMANN, GN
    GOTOH, A
    KAO, CH
    ZHANG, WW
    CHUNG, LWK
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 423 - 423
  • [24] Combining Androgen Deprivation and Immunotherapy in Prostate Cancer Treatment: A Mechanistic Approach
    Barnaby, Johnna
    Jain, Harsh Vardhan
    APPLIED SCIENCES-BASEL, 2022, 12 (14):
  • [25] Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells
    Yeung, F
    Li, XY
    Ellett, J
    Trapman, J
    Kao, CH
    Chung, LWK
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (52) : 40846 - 40855
  • [26] Reprogramming Leukemia Cells into Antigen Presenting Cells As a Novel Cancer Vaccination Immunotherapy
    Linde, Miles Hamilton
    Dove, Christopher G.
    Gurev, Sarah F.
    Phan, Paul
    Zhao, Feifei
    Miller, Lindsay P.
    Majeti, Ravindra
    BLOOD, 2019, 134
  • [27] Reprogramming leukemia cells into antigen presenting cells as a novel cancer vaccination immunotherapy
    Linde, Miles H.
    Dove, Christopher G.
    Gurev, Sarah F.
    Phan, Paul
    Zhao, Feifei
    Gars, Eric J.
    Marshall, Payton L.
    Miller, Lindsay P.
    Majeti, Ravindra
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [28] \#915;\#948; T cells are new antigen presenting cells for cancer immunotherapy
    Yamasaki, Akio
    Nakamura, Masafumi
    Sato, Norihiro
    Morisaki, Takashi
    Tanaka, Masao
    Katano, Mitsuo
    CANCER RESEARCH, 2009, 69
  • [29] Evaluation of gammadelta T cells as antigen-presenting cells for cancer immunotherapy
    Yamasaki, A.
    Onishi, H.
    Morisaki, T.
    Tanaka, M.
    Katano, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer
    Morote, J
    Trilla, E
    Esquena, S
    Abascal, JM
    Reventos, J
    INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (06) : 877 - 881
12345